Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00970138
Other study ID # 2009APA-MGC
Secondary ID
Status Completed
Phase Phase 2/Phase 3
First received September 1, 2009
Last updated July 11, 2011
Start date June 2009
Est. completion date December 2010

Study information

Verified date September 2010
Source Fudan University
Contact n/a
Is FDA regulated No
Health authority China: Ethics Committee
Study type Interventional

Clinical Trial Summary

Apatinib is a tyrosin-inhibitor agent targeting at vascular endothelial growth factor receptor (VEGFR), and it's anti-angiogenesis effect has been viewed in preclinical tests. The investigators' phase I study has shown that the drug's toxicity is manageable and the maximum tolerable daily dose is 850 mg. The purpose of this study is to determine whether apatinib can improve progression free survival compared with placebo in patients with metastatic gastric carcinoma who failed two lines of chemotherapy.


Description:

Up to now, although FU based, cisplatin based and taxane based regimen, and ECF regimen have been suggested as the first line therapy for A/MGC by FDA, the efficacy of these treatment is still unsatisfied for their toxicity and limitation in prolonging survival. Based on the promising results of apatinib in the phase I study, this clinical trial has been designed to evaluate whether apatinib can improve progression free survival in patients with metastatic gastric carcinoma who failed two lines of chemotherapy compared with placebo. Patients will be randomized to 3 groups, one group patients will receive the treatment of apatinib 850mg qd, one group patients will receive apatinib 425mg bid, and the other group will receive placebo.


Recruitment information / eligibility

Status Completed
Enrollment 141
Est. completion date December 2010
Est. primary completion date October 2010
Accepts healthy volunteers No
Gender Both
Age group 18 Years to 70 Years
Eligibility Inclusion Criteria:

- = 18 and = 70 years of age

- Histologically confirmed advanced or metastatic adenocarcinoma of the stomach

- Have failed for 2 lines of chemotherapy

- Life expectancy of more than 3 months

- ECOG performance scale = 2

- At least one measurable lesion (larger than 10 mm in diameter by spiral CT scan)

- Duration from the last therapy is more than 6 weeks for nitroso or mitomycin

- More than 4 weeks for operation or radiotherapy

- More than 4 weeks for cytotoxic agents or growth inhibitors

- Adequate hepatic, renal, heart, and hematologic functions (platelets > 80 × 109/L, neutrophil > 2.0 × 109/L, serum creatinine = 1.5mg/dl, total bilirubin within upper limit of normal(ULN), and serum transaminase=2.5×the ULN).

Exclusion Criteria:

- Pregnant or lactating women

- History of other malignancies except cured basal cell carcinoma of skin and carcinoma in-situ of uterine cervix

- Any factors that influence the usage of oral administration; Evidence of CNS metastasis

- History of another malignancy within the last five years except cured basal cell carcinoma of skin and carcinoma in-situ of uterine cervix

- Intercurrence with one of the following: hypertension, coronary artery disease, arrhythmia and heart failure

- Receiving the therapy of thrombolysis or anticoagulation

- Abuse of alcohol or drugs

- Allergy to the ingredient of the agent or more than two kinds of food and drug

- Less than 4 weeks from the last clinical trial

- Disability of serious uncontrolled intercurrence infection.

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment


Related Conditions & MeSH terms


Intervention

Drug:
apatinib tablet
A850: apatinib 850 mg qd p.o. plus placebo qd p.o. until disease progression or intolerable toxicity or patients withdrawal of consent B425: apatinib 425 mg bid p.o. until disease progression or intolerable toxicity or patients withdrawal of consent Cpla: placebo bid p.o. until disease progression or intolerable toxicity or patients withdrawal of consent

Locations

Country Name City State
China Fudan University Cancer Hospital ShangHai Shanghai

Sponsors (1)

Lead Sponsor Collaborator
Fudan University

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary Progression free survival 8 weeks Yes
Secondary Overall survival safety 8 weeks Yes
Secondary DCR (Disease control rate) 8 weeks No
Secondary ORR (Objective response rate) 8 weeks No
Secondary QoL (Quality of life) 8 weeks Yes
Secondary Toxicity 8 weeks Yes
See also
  Status Clinical Trial Phase
Active, not recruiting NCT04602026 - The RIOT Trial: Re-Defining Frailty and Improving Outcomes With Prehabilitation for Pancreatic, Liver, or Gastric Cancer N/A
Not yet recruiting NCT03599778 - XELOX Combined With Apatinib as Post-operative Chemotherapy in Locally Advanced Gastric Adenocarcinoma Phase 1/Phase 2
Terminated NCT00256321 - Celecoxib/Oxaliplatin/Capecitabine for Gastric/Gastroesophageal Junction Carcinoma Phase 2
Recruiting NCT04147494 - Experimental PET Imaging Scans Before Cancer Surgery to Study the Amount of PET Tracer Accumulated in Normal and Cancer Tissues Early Phase 1
Recruiting NCT02617134 - CAR-T Cell Immunotherapy in MUC1 Positive Solid Tumor Phase 1/Phase 2
Recruiting NCT02317471 - Immunotherapy of Gastric Cancer With Autologous Tumor Derived Heat Shock Protein gp96 Phase 1/Phase 2
Active, not recruiting NCT03735511 - A Real World Study of Apatinib in Treatment of Patients With Gastric Carcinoma
Recruiting NCT04410302 - Patient-Derived Xenografts to Reduce Cancer Health Disparities
Recruiting NCT05596188 - Anxiety Before Non-cardiac Surgery in Adults
Recruiting NCT02611024 - Pharmacokinetic Study of Lurbinectedin in Combination With Irinotecan in Patients With Selected Solid Tumors Phase 1/Phase 2
Terminated NCT04254107 - A Safety Study of SEA-TGT (SGN-TGT) in Advanced Cancer Phase 1
Recruiting NCT01348009 - Tesetaxel Plus Capecitabine and Cisplatin in Advanced Gastric Cancer Phase 1/Phase 2
Recruiting NCT00639522 - Dose Escalation Study of Liposomal Paclitaxel With/Without Capecitabine in Patients With Advanced Gastric Carcinoma Phase 1
Recruiting NCT05811546 - Immunohistochemical Evaluation of DNA Methylation and Histone Modification in H. Pylori Associated Gastric Carcinoma
Recruiting NCT05229809 - Clinical Trial of Yiqi Wenyang Jiedu Prescription in the Prevention and Treatment of Postoperative Metastasis and Recurrence of Gastric Cancer Phase 4
Recruiting NCT02409199 - A Study of Apatinib Versus Docetaxol Patients With Advanced Gastric Cancer Phase 2/Phase 3
Recruiting NCT06408220 - Risk Assessment Evaluation for Identifying Participants at High Risk for Stomach Cancer N/A
Recruiting NCT04443036 - Clinical Study of Nab-paclitaxel Combined With Toripalimab in Local Advanced or Metastatic G/GEJ Carcinoma N/A
Active, not recruiting NCT04505553 - Oral Cryotherapy Plus Acupressure and Acupuncture Versus Oral Cryotherapy for Decreasing Chemotherapy-Induced Peripheral Neuropathy From Oxaliplatin-Based Chemotherapy in Patients With Gastrointestinal Cancer Phase 2
Recruiting NCT02839954 - CAR-pNK Cell Immunotherapy in MUC1 Positive Relapsed or Refractory Solid Tumor Phase 1/Phase 2